Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States.
Chatterjee A, Shapouri S, Manzoor BS, Ravelo A, Sail K, Qendri V, van de Wetering G, Davids MS. Chatterjee A, et al. Among authors: manzoor bs. J Manag Care Spec Pharm. 2021 Nov;27(11):1532-1544. doi: 10.18553/jmcp.2021.27.11.1532. J Manag Care Spec Pharm. 2021. PMID: 34714110 Free PMC article.
Budget Impact of 12-Month Fixed Treatment Duration Venetoclax in Combination with Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia Patients in the United States.
Cho SK, Manzoor BS, Sail KR, Parisé H, Ravelo A, Shapouri S, Kapustyan T, Sharmokh S, Virabhak S, Davids MS, Johnson S. Cho SK, et al. Among authors: manzoor bs. Pharmacoeconomics. 2020 Sep;38(9):941-951. doi: 10.1007/s40273-020-00919-1. Pharmacoeconomics. 2020. PMID: 32383129
Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.
Fakhri B, Emechebe N, Manzoor BS, Jawaid D, Alhasani H, Edwards M, Tuncer HH. Fakhri B, et al. Among authors: manzoor bs. JCO Oncol Pract. 2024 Aug;20(8):1132-1139. doi: 10.1200/OP.23.00630. Epub 2024 Apr 16. JCO Oncol Pract. 2024. PMID: 38626366 Free PMC article.
Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
Shadman M, Manzoor BS, Sail K, Tuncer HH, Allan JN, Ujjani C, Emechebe N, Kamalakar R, Coombs CC, Leslie L, Barr PM, Brown JR, Eyre TA, Rampotas A, Schuh A, Lamanna N, Skarbnik A, Roeker LE, Bannerji R, Eichhorst B, Fleury I, Davids MS, Alhasani H, Jiang D, Hill BT, Schuster SJ, Brander DM, Pivneva I, Burne R, Guerin A, Mato AR. Shadman M, et al. Among authors: manzoor bs. Clin Lymphoma Myeloma Leuk. 2023 Jul;23(7):515-526. doi: 10.1016/j.clml.2023.03.010. Epub 2023 Mar 24. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37076367 Free article.
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Šimkovič M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR. Thompson MC, et al. Among authors: manzoor bs. Blood Adv. 2022 Aug 9;6(15):4553-4557. doi: 10.1182/bloodadvances.2022007812. Blood Adv. 2022. PMID: 35736670 Free PMC article. No abstract available.
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy.
Cochrane T, Enrico A, Gomez-Almaguer D, Hadjiev E, Lech-Maranda E, Masszi T, Nikitin E, Robak T, Weinkove R, Wu SJ, Manzoor BS, Busman T, Pai M, Komlosi V, Anderson MA. Cochrane T, et al. Among authors: manzoor bs. Leuk Lymphoma. 2024 Nov;65(11):1743-1746. doi: 10.1080/10428194.2023.2247511. Epub 2023 Aug 25. Leuk Lymphoma. 2024. PMID: 37626019 Free article. No abstract available.
21 results